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Abstract 
Decreased levels of endogenous hydrogen sulfide (H2S) contribute to atherosclerosis, 
whereas equivocal data are available on H2S effects during sepsis. Moreover, H2S improved 
glucose utilization in anaesthetized, ventilated, hypothermic mice, but normothermia and/or 
sepsis blunted this effect. The metabolic effects of H2S in large animals are controversial. 
Therefore, we investigated the effects of the H2S donor GYY4137 during resuscitated, fecal 
peritonitis-induced septic shock in swine with genetically and diet-induced coronary artery 
disease (CAD). 12 and 18 hours after peritonitis induction, pigs received either GYY4137 (10 
mg·kg-1, n=9) or vehicle (n=8). Before, at 12 and 24 hours of sepsis, we assessed left 
ventricular (pressure-conductance catheters) and renal (creatinine clearance, blood NGAL 
levels) function. Endogenous glucose production and glucose oxidation were derived from 
the plasma glucose isotope and the expiratory 13CO2/12CO2 enrichment during continuous i.v. 
1,2,3,4,5,6-13C6-glucose infusion. GYY4137 significantly increased aerobic glucose 
oxidation, which coincided with higher requirements of exogenous glucose to maintain 
normoglycemia, as well as significantly lower arterial pH and decreased base excess. Apart 
from significantly lower cardiac eNOS expression and higher troponin levels, GYY4137 did 
not significantly influence cardiac and kidney function or the systemic inflammatory 
response. During resuscitated septic shock in swine with CAD, GYY4137 shifted metabolism 
to preferential carbohydrate utilization. Increased troponin levels are possibly due to reduced 
local NO availability. Cautious dosing, the timing of GYY4137 administration and 
interspecies differences most likely account for the absence of any previously described anti-
inflammatory or organ-protective effects of GYY4137 in this model. 
 
Keywords: gluconeogenesis, glucose oxidation, eNOS, iNOS, CSE, HO-1, 3-nitrotyrosine, 
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Introduction 
Recent rodent studieshave demonstrated thatimpaired endogenous hydrogen sulfide (H2S) 
productionis implicated inthe pathogenesisof atherosclerosis(1). However, equivocal results 
are available on H2S levels in patients with coronary artery disease (CAD): both reduced (2) 
and increased H2S plasma levels (3) were described.  
H2S was also reported to affect glucose metabolism:Increased gluconeogenesis in hepatocytes 
following stimulation with sodium hydrosulfide (NaHS) was demonstrated in vitro (4), 
whereas CSE (cystathionine γ-lyase) knockout mice revealed reduced gluconeogenesis (5). 
Previously, we demonstrated that inhaled H2S increased glucose oxidation in anaesthetized 
and mechanically ventilated mice during hypothermia, whereas both normothermiaand/or 
sepsis blunted this effect (6).  
The vast majority of data on H2S with respect to glucose metabolism and cardiovascular 
properties originate from healthy small animal models, where H2S is able to induce profound 
hypometabolism(7). The metabolic properties of H2S in large animal modelsare controversial, 
inasmuch as both absence of metabolic effects (8-10) as well as reduced energy expenditure 
(11)were reported. Thus, therelevance and translatability of H2S effects reported in small 
animals has been questioned for large animal models or humans(6, 12).  
Due to the plethora of cardiovascular and metabolic effects of H2S, H2S-donating or 
inhibiting compounds are considered as promising future therapeutic options. While 
inhalation of gaseous H2S is associated with pulmonary toxicity and airway irritation, 
intravenous application of sulfide salts face extremely narrow timing and dosing margins 
(13).GYY4137 (morpholin-4-ium-4-methoxyphenyl(morpholino) phosphinodithioate) is a 
slow-releasing H2S donor with improved pharmacokinetics and a more constant release of 
H2S compared to the instantaneous liberation by conventional sulfide salts (14), thus more 
closely mimicking endogenous H2S release. GYY4137 demonstrated anti-inflammatory 
effects upon lipopolysaccharide (LPS)stimulation both in vitro and in rodentsin vivo (15, 
16).Up to now, no data are available about GYY4137 in large animals. Given the importance 
of H2S in cardiovascular pathophysiology and its ambiguous metabolic role in large animals, 
we investigated the effects ofGYY4137 in a clinically relevant porcine model of resuscitated 
septic shock with pre-existing atherosclerosis-induced CAD. 
 
Materials and Methods 
Animals 
The study was approved by the University of Ulm Animal Care Committee and the Federal 
Authorities for Animal Research (animal experiment number 1098, date of approval by the 
RegierungspräsidiumTübingen: 22.05.2012). The experiments were performed in adherence 
with the National Institute of Health Guidelines on the Use of Laboratory Animalsand the 
European Union “Directive 2010/63/EU on the protection of animals used for scientific 
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purposes”. Eighteen castrated male familial hypercholesterolemia BretoncellesMeishan 
(FBM) pigs with a median age of 19 months (interquartilerange (IQR): 18 to 20 months) and 
a median weight of 59 kg (IQR: 55 to 62 kg)were recruited for the study. One pig from the 
vehicle group was excluded from the study, as it had not developed diffuse peritonitis upon 
necropsy. Moreover, the pig did not require norepinephrinesupport, and thus, by definition, 
did not develop septic shock. Subsequent data refer to the 17 pigs included in the data 
analysis. The FBM pig strain is a cross-bread of Rapacz pigs with smaller strains (Chinese 
Meishan and Bretoncelles), characterized by a homozygous R84C low-density lipoprotein 
(LDL) receptor mutation, and develops marked atherosclerosis and consecutive CAD 
uponatherogenic diet(17). Animals received the diet (1 kg daily, 1.5 % cholesterol, 20 % 
bacon fat) for at least 9 months prior to the experiments. The phenotype has been 
characterized previously. Briefly, FBM pigs on atherogenic diet exhibit significantly higher 
cholesterol levels compared to healthy German landrace swine of the same age. Plasma levels 
of isoprostanes are significantly increased, while plasma nitrite/nitrate levels are significantly 
lower than in healthy control strains. FBM pigs are also characterized by a significantly lower 
creatinine clearance compared to healthy German landrace swine(18). 
Anesthesia 
Before the experiments, pigs were fasted for 12 hours with free access to water. 
Intramuscular premedication consisted of 5 mgkg-1azaperone. After establishment of an 
intravenous access via ear vein, anesthesia was induced with propofol (1-2 mgkg-1) and 
ketamine (1-2 mgkg-1). The pigs were endotracheally intubated and mechanically ventilated 
(tidal volume 8 mlkg-1, respiratory rate 8 – 12min-1adapted to achieve an arterial pCO2 of 
35 – 40 mmHg, inspiratory/expiratoy (I/E) ratio 1:1.5, fraction of inspiratory oxygen (FiO2) 
30%, positive end expiratory pressure (PEEP) 10 cm H2Oto prevent formation of atelectasis, 
peak airway pressure ≤ 40 mmHg). Anesthesia was maintained with continuous intravenous 
infusion of pentobarbitone (8 – 12 mgkg-1h-1). Burprenorphine was used for analgesia (30 
µgkg-1 initially, further 10 µgkg-1 every 8 hours as well as prior to surgery and induction 
of fecal peritonitis). Pancuronium (0.15 mgkg-1h-1) ensured muscle relaxation.  Balanced 
electrolyte solutions (20 mlkg-1h-1, Jonosteril 1/1, Fresenius, Bad Homburg, Germany) 
were infused for fluid homeostasis. During surgery, hydroxyethyl starch 6% 130/0.42 
(Vitafusal, Serumwerk, Bernburg, Germany) was used to maintain filling pressures. External 
heating allowed to control and maintain body core temperature at 37.5 – 38.5° Celsius. 
Surgical procedures 
The right internal jugular veinwas exposed and a9Fcentral venous catheter sheath was 
inserted. The central venous catheter was subsequently used for infusion therapy and 
application of intravenous drugs. A balloon-tipped thermodilution pulmonary artery catheter 
was inserted via the sheath and used for the measurement of central venous pressure (CVP), 
mean pulmonary artery pressure (MPAP), pulmonary artery occlusion pressure (PAOP) and 
cardiac output (CO). One femoral artery and the left carotid artery were exposed for 
placement of a PiCCO® catheter for continuous cardiac output measurement and an 8F 
arterial catheter sheath, respectively. A pressure-conductance catheter (CD Leycom, Hengelo, 
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The Netherlands) was inserted via the latter, and advanced into the left ventricle (LV) under 
control of the pressure curve. In order to determine kidney blood flow, a laparotomy was 
performed, and an ultrasonic flow probe was placed around the right kidney artery.Following 
exposure of a femoral vein, a 4F catheter was advanced into the inferior vena cava and 
guided into the right renal vein under manual and visual control. An indwelling catheter in 
the urinary bladder allowed urine collection. Two tubes were placed through the abdominal 
wall into the peritoneal cavity for subsequent induction of peritonitis.  
Experimental protocol 
After four hours of surgery, pigs were allowed to recover for eight hours before baseline data 
were collected. Subsequently, fecal peritonitis was induced. For this purpose, 1 gkg-1 
autologous feces was collected during premedication, dissolved in 500 ml 0.9% saline and 
incubated at 38° Celsius for 12 hours. 3 mlkg-1of the supernatant were injected into the 
peritoneal cavity via the abdominal tubes. 12 and 18 hours after induction of peritonitis, 
animals received bolus injections of 10 mgkg-1 GYY4137 (n=9) or vehicle (saline, n=8). 
GYY4137 was synthesized in-house as previously described (14). Based on the time course 
of fecal peritonitis in previous sepsis studies of our group(19), where norepinephrine 
requirements to maintain baseline MAP indicated the onset of sepsis-induced hemodynamic 
alterations after 6 to 9 hours after peritonitis induction, the administration of GYY4137 was 
carried out as a “therapeutic approach” after development of sepsis. Balanced electrolyte 
solutions (20 mlkg-1h-1) were continuously infused, and reduced to 10 mlkg-1h-1 if 
PAOP > 18 mmHg. If MAP remained below baseline values despite volume resuscitation, 
norepinephrine was used to stabilize MAP at pre-peritonitis values. However, infusion rates 
of norepinephrinewere not further increased, if the heart rate was higher than 160 min-1 in 
order to avoid tachycardia-induced myocardial ischemia. Respirator settings were modified 
(I/E ratio 1:1, PEEP 12 or 15 cm H2O) during the experiments when the ratio of the arterial 
oxygen partial pressure (paO2) to FiO2 dropped below 300 or 200 mmHg, respectively. FiO2 
was stepwise adjusted to maintain apaO2 of 70-90 mmHg. At the end of the experiment, pigs 
were euthanized under deep anesthesia via injection of potassium chloride.  
Measurements and calculations 
Immediately before, 12 and 24 hours after induction of fecal peritonitis, data sets were 
collected. Measurements included haemodynamics (MAP, MPAP, PAOP, CVP, heart rate, 
CO), gas exchange (calorimetric CO2 production, arterialand mixed venous blood gases 
(paO2, paCO2)),pH, base excess, glucose, lactate, β-hydroxybutyrate and the plasma levels of 
troponin, interleukin (IL)-6, IL-1β, tumor necrosis factor alpha (TNFα), nitrite plus nitrate 
(NO2- + NO3-) and 8-isoprostane. The pressure-conductance catheter allowed assessment of 
systolic and diastolic LV function. Renal function was assessed by determination of the 
following parameters: urine output, right kidney artery flow, renal venous blood gases, 
plasma creatinine andneutrophil gelatinase-associated lipocalin (NGAL) concentrations and 
creatinine clearance.  
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Using a steady state approach, endogenous glucose production was calculated after 
determination of plasma glucose isotope enrichment by combined gas chromatography/mass 
spectrometry (GC/MS) and correction for exogenous glucose administration during 
continuous intravenous infusion of stable, non-radioactively labeled 1,2,3,4,5,6-13C6-glucose 
(tracer). Pigs received an initial priming dose of 400 mg of tracer over three hours. 
Subsequently, the tracer was continuously infused at a rate of approximately 0.025 mgkg-
1min-1 until the end of the experiment. Additional analysis of the enrichment of 
13CO2/12CO2 isotope in the expiratory gas using non-dispersive infrared spectrometry together 
with the calorimetric determination of total CO2 production allowed the calculation of the 
percentage of oxidized tracer and totalaerobic glucose oxidation rate(19). 
Free blood sulfide concentrations were determined by combined GC/MS(20).  
Kidney and heart specimen were immediately collected post-mortem and analyzed for protein 
expression of heme oxygenase-1 (HO-1), B-cell lymphoma-extra large (Bcl-xL), inhibitor of 
nuclear factor kappa B (IκBα), the constitutive, endothelial and the inducible isoforms of 
thenitric oxide synthase (eNOS, iNOS) by western blotting. Activation of the nuclear 
transcription factor kappa B (NF-κB) was assessed by electrophoretic mobility shift assay 
(EMSA). Actin and vinculin served as loading controls. For comparison between individual 
gels, the intensity of each band was related to that of the mean of two native animals, which 
had not undergone surgical instrumentation and fecal peritonitis. Western blots were run at 
least in triplicates. The mean value of the individual gels for each animal was usedfor 
quantitative analysis, and data are reported as fold increase over the mean of the two native 
animals. Supplemental figure 1, http://links.lww.com/SHK/A550, shows original western 
blots and EMSA for kidney (A) and heart (B) of all individual animals. 
Additional heart and kidneyspecimens were taken for immunohistochemistry analysis of 3-
nitrotyrosine formation, expression of the endogenous H2S-producing enzyme CSE and 
extravascular albumin. Therefore, specimen were fixed in formalin, embedded in paraffin, 
dewaxed in xylene, and rehydrated with a graded series of ethanol. After incubation in citrate 
buffer and boiling for heat-induced antigen retrieval, samples were blocked with goat sera 
and subsequently incubated with primary anti-nitrotyrosine (polyclonal rabbit; Merck 
Millipore, Darmstadt, Germany), anti-CSE (monoclonal mouse; Abnova, Taipei City, 
Taiwan) or anti-albumin antibodies (polyclonal rabbit; Abcam, Cambridge, United 
Kingdom). Primary antibody detection was performed by using the Dako REAL Detection 
system/RED(Dako Deutschland GmbH, Hamburg, Germany),followed by counterstaining 
with haematoxylin. Slides were visualized using a Zeiss Axio Imager A1 microscope with a 
x10 objective. Quantification for intensity was performed using the AxioVision 4.8 software 
(Zeiss, Jena, Germany). Results are presented as meandensitometric sum red(19).  
Mitochondrial respiratory activity was analyzed via “high-resolution respirometry” using the 
Oroboros Oxygraph-2K (Oroboros Instruments, Innsbruck, Austria) in homogenized cardiac, 
renal and hepatic tissue specimens collected at the end of the experiment. After 
supplementation of substrates for complexes I and II and ADP, maximal oxidative 
phosphorylation (in the coupled state, OxPhos) was assessed. Maximal respiratory capacity 
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of the electron transfer system (ETS) in the uncoupled state was measured after addition of 4-
(trifluoromethoxy) phenylhydrazone (FCCP). Additionally, LEAK respiration compensating 
for proton leakage or slipping was reported as percentage of ETS capacity(21). 
 
Statistical analysis 
All data are expressed as median (IQR) unless otherwise stated. The effects of GYY4137 
were analyzed using repeated measures (RM) two-way ANOVAs. P values for effects of time 
and treatment are reported in the data tables. Subsequent post-hoc testing within the 
ANOVAs was corrected for multiple comparisons (Sidak method). As GYY4137 was 
administered 12 and 18 hours after the induction of fecal peritonitis, i.e., after the 12 hour 
time point, the ANOVAs were performed with the 12 hour time point as baseline (before 
administration of GYY4137) and the 24 hour time point (after administration of GYY4137). 
Inter-group differences of data with only one data set (e.g. histology at the end of the 
experiments etc.) were analyzed by the Mann-Whitney rank sum test. A p value of less than 
0.05 was considered statistically significant. GraphPad Prism 7 software was used for 
statistical evaluation and graphical display.A statistical sample size calculation based on 
creatinine levels and norepinephrine requirements of a previous study (13)and a power of 
80% yielded a minimum of n=8 animals per group. In order to compensate for non-normal 
distribution of parameters, n=9 animals were recruited per group.The results should be 
interpreted carefully in an explorative manner due to the small sample size and the multitude 
of analyzed variables. 
 
Results 
Table 1 shows that sepsis and resuscitation causeda normotensive, hyperdynamiccirculation 
in both groups. Comparable high doses of norepinephrine (0.90 (0.82; 1.18) vs 0.85 (0.54; 
1.30) µgkg-1min-1, p=0.96) were required to maintain MAP in the GYY4137 and the 
control group, respectively. Further hemodynamic parameters (CVP, MPAP, PAOP) were 
also similar between groups. PaO2and the paO2 to FiO2 ratio significantly declined after 24 
hours, again without any intergroup differences.  
Metabolic data before induction of fecal peritonitis comprising temperature, pH, base excess, 
plasma lactate, β-hydroxybutyrate(table 1), blood glucose, endogenous glucose production, 
glucose oxidation and CO2 production from glucose oxidation (figure 1) were similar in the 
two groups.Endogenous glucose release slightly increased after 12 hours of peritonitis 
induction, and thereafter even decreased again in both groups (figure 1). After administration 
of GYY4137, pigs showed significantly higher tracer oxidation (p=0.041) and total glucose 
oxidation rate (p=0.020)at 24 hours compared to control animals, resulting in significantly 
higher requirement of exogenous glucose administration to maintain normoglycemia 
(p=0.018) (figure1). While total CO2 production remained constantin both groups between 12 
and 24 hours after induction of fecal peritonitis (table 1), the fraction of CO2 production from 
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glucose oxidation was significantly higher at 24 hours in the GYY4137-treated 
animals(p=0.031, figure 1). 
Both arterial pH and base excess decreased after infusion of GYY4137(p<0.001 and p=0.051, 
respectively). PH was significantly lower compared to vehicle at 24 hours (p<0.001), whereas 
lactate levels were comparable (table 1).Plasma sulfide levels did not significantly differ in 
the two groups either (table 2). 
Table 3 demonstrates that blood biomarkers of inflammation and oxidative stress as well as 
nitrite/nitrate plasma levels did not significantly differ after 24 hours. However, blood 
isoprostanes were higher in the GYY4137 group 12 hours after induction of peritonitis, i.e. 
prior to the first injection of GYY4137.  
Parameters of left ventricular function did not reveal substantial intergroup differences. 
However, troponin levels significantly increasedin the GYY4137-treated pigs compared to 
before treatment (p=0.01) and were higher than in the control group at 24 hours (p=0.059, 
table 4). While cardiac Bcl-xL and HO-1 showed a non-significant trend towards reduced 
expression (both p=0.07), cardiac eNOS expression was significantly lower upon GYY4137 
treatment (p=0.001, figure 2).  
Apart from lower renal venous base excess (p=0.001) in the GYY4137 group at 24 hours, 
analysis of kidney function(table 5) and quantitative analysis of western blots for renal Bcl-
xL, HO-1, IκBα and iNOSexpression as well as EMSA for NF-κB activation (figure 3) did 
not show any further significant intergroup differences. Immunohistochemistry for renal and 
cardiac CSE expression, nitrotyrosine formation and extravascular albumin (figure 4), as well 
as mitochondrial respiratory capacity (Oxphos, ETS, LEAK/ETS) of cardiac, renal or hepatic 
tissue specimens (supplemental table 1, http://links.lww.com/SHK/A551) did not show any 
significant intergroup differences, either.  
 
Discussion 
Metabolic effects 
In the present study, we investigated the effects of the slow-releasing hydrogen sulfide donor 
GYY4137 in a porcine model of resuscitated septic shock with pre-existing CAD. The main 
findings were significantly increased glucose oxidation (figure 1) and reduced arterial pH as 
well as base excess (table 1) in the GYY4137-treated pigs. As total CO2 production did not 
increase, the higher glucose oxidation in the GYY4137 group supports the notion that 
GYY4137 treatment resulted in preferential carbohydrate utilization. Consistently, inhaled 
hydrogen sulfide also increased aerobic glucose oxidation in anesthetized and mechanically 
ventilated, hypothermic mice(6). Interestingly, in that study, normothermiaand/or sepsis 
blunted the shift in substrate utilization. As both the metabolic rates and the metabolic 
response to stress substantially vary between small and large animals, interspecies differences 
might be responsible for the heterogeneous effects. Small rodents are able to rapidly reduce 
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their oxygen consumption and typically drop their core temperature in response to stress by 
reducing non-shivering thermogenesis without affecting ATP generation (6, 12), and H2S-
inducedhypometabolismis well described(7, 22). In contrast, the decrease of the metabolic 
rate upon H2S treatment remains a matter of debate in large animals or humans. In line with 
previous studies in pigs(9) or sheep (8, 10), H2S-induced hypometabolism was absent in our 
study. Of note, while data from large animals were collected under anesthesia, the metabolic 
effects of H2S in small mammals were predominantly reported in awake, spontaneously 
breathing mice(7) or rats (22). General anesthesia seems at least to attenuatehypometabolic 
effects of H2S in mice(6).  
Several studies demonstrated effects of H2S on glucose metabolism. Stimulation of 
hepatocytes with NaHS impaired glucose utilization and increased gluconeogenesis in 
vitro(4), whereasgenetic knockout of CSE decreased gluconeogenesis in mice (5). Incultured 
cardiomyocytes, NaHS, supported glucose uptake and metabolism in (23).Thus, H2S might 
function as a provider of increased carbohydrate substrate availability by increasing hepatic 
glucose synthesis and by facilitating glucose utilization by other organs. Moreover, 
GYY4137 has been shown to inhibit lipolysis in vivo in micereceiving a high fat diet 
(24),further supporting a H2S-induced shift in substrate utilization. Any shift towards 
carbohydrate oxidation entails an improved yield of the oxidative phosphorylation, as the net 
ATP production per mole of consumed oxygen is higher for carbohydrate than lipid oxidation 
(25). 
Besides the influence of GYY4137 on glucose oxidation, pH was significantlylower at 24 
hours of sepsis, and base excess decreased in the GYY4137 group.In contrast, plasma lactate 
levels were comparable (table 1). Hence, analyzing the strong ion difference (SID), the 
lactate levels could not account for the lower base excess. Accumulation of unmeasured acids 
such as free fatty acids due to the metabolic shift towards glucose utilization would be 
conceivable. However, β-hydroxybutyrate did not significantly differ among groups and even 
decreased at the end of the experiment in the GYY group (table 1). As both inhibitory and 
stimulatory effects of hydrogen sulfide on mitochondrial respiration have been described(26), 
we further excluded a possible toxic effect of GYY4137 on the mitochondrial respiratory 
capacity (supplemental table 1, http://links.lww.com/SHK/A551) as cause for the metabolic 
acidosis. Importantly, the mitochondrial results need to be interpreted very carefully:On the 
one hand,sample treatment and ex-vivo conditions might have blunted potential in vivo 
effects. On the other hand, as GYY4137 is not specifically targeted to the mitochondria, the 
amount of H2S reaching the mitochondria might have been too low to provoke substantial 
effects. The effects of GYY4137 on the acid-base state remain elusive so far and deserve 
future investigation. 
Non-metabolic results 
Troponin levels were higher in the GYY4137 groupat 24 hours (table 4). However, a trend 
towards increased troponin was already present 12 hours after induction of fecal peritonitis, 
i.e. prior to the injection of GYY4137. At that time point, plasma levels of 8-isoprostane were 
also higher than in the control group (table 3, p=0.049). Moreover, cardiac HO-1 expression 
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was lower in the GYY4137-treated pigs (figure 2). Finally, despite overall comparable doses 
of norepinephrine, the GYY4137-treated animals showed a tendency to increased cumulative 
dosesof norepinephrine within the first 12 hours after induction of (0.61 (0.56; 0.79) vs 0.36 
(0.28; 0.81) µgkg-1min-1; p=0.11). Thus, both more pronounced oxidative stress and 
enhanced myocardial O2 demand resulting from higher norepinephrine needs might 
explainthe increased troponin levels independently of GYY4137. After administration of 
GYY4137, 8-isoprostane levels slightly decreased supporting a previously 
describedantioxidative role of GYY4137 in the heart (27). However, in contrast to studies in 
rodents reporting both NO-dependent and NO-independent cardioprotective effects of 
GYY4137 (28, 29), myocardial eNOS expression was significantly lower in the GYY4137-
treated animals (figure 2). Consequently, reduced local availability of NO might have further 
contributed to cardiac injury. Of note, troponin levels were also elevated in a dose-dependent 
manner in a porcine model of cardiac arrest and resuscitation during supplementation of 
Na2S(30). Interspecies differences or the pre-existing cardiac comorbidity might account for 
the different results. 
In contrast to conventional sulfide donors (gaseous application, sulfide salts), GYY4137 
more consistently displayed anti-inflammatory features in previous studies, both in vitro and 
in vivo(15, 16).Moreover, GYY4137reduced kidney and liver damage during endotoxic 
shockin vivo (15).These anti-inflammatory and organ-protective properties of GYY4137 
could not be demonstrated in the present study. However, all previous dataon organ-
protective effects of GYY4137 originate from studies in small mammals. Furthermore, 
intensive care measures and, in particular, the high-dose vasopressor support may have 
blunted potential GYY4137-mediated effects, as norepinephrine is well-established to have 
pro-oxidant properties, especially in the heart (31), andexisting murine studies do not 
comprise standard ICU and catecholamine therapy. The pre-existing atherosclerotic 
comorbidity might also be accountable for the discrepant results. Decreased 
endogenousH2Sproductionhas been implicated in the development atherosclerosis(1). Finally, 
the most important aspects to consider are timing anddosing of GYY4137. As no studies 
about GYY4137 in large animals have been reported so far, dosing of GYY4137 was selected 
according to previous rodent experiments (14). In the initial study characterizing the novel 
compound GYY4137, a low dose of 26.6 µmolkg-1 already caused a fall in MAP of more 
than 5 mmHg in rodents (14). In the present study, two boli of 10 mgkg-1 (26.6 µmolkg-1) 
GYY4137 were administered 12 and 18 hours after peritonitis induction, and higher doses 
were not usedin order to avoid aggravation of sepsis-induced hypotension due to vasodilatory 
effects of H2S. Hence, the dose of GYY4137 may have limited the findings with respect to 
anti-inflammatory and organ-protective properties, and higher doses might have yielded 
further results, especially as H2S liberation from GYY4137 has been shown to be rather 
slowly and less efficient compared to novel compounds(32). In addition, timing represents a 
crucial aspect for the efficacy of GYY4137 and H2S-based therapies(13): The anti-
inflammatory and organ-protective properties of GYY4137 in endotoxic shock in rats could 
only be seen when GYY4137 was given shortly (1 or 2 hours) after LPS injection, whereas a 
pre-treatment design failed to induce significant anti-inflammatory effects (15). Due to 
temporal differences in the evolution of sepsis-induced alterations between the rodent model 
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of endotoxic shock and our porcine model of fecal peritonitis, GYY4137 was given 12 and 18 
hours after induction of peritonitis in the present study, when sepsis had fully 
developed.Thus, the dose of GYY4137 and the clinically relevant post-treatment 
administration of GYY4137might account for the absence of anti-inflammatory and organ-
protective results in the present study. 
Measurement of free blood sulfide levels did not reveal significant differences between the 
GYY4137 and the control group (table 2). However, application of exogenous H2S is not 
necessarily reflected in increased free sulfide blood levels due to the high sulfide-binding 
capacity of blood (33).Spiking of blood samples ex vivo with sodium sulfide to reach a target 
concentration of 100µM only increased sulfide blood levels to about 20µM (20). Moreover, 
in a previous study from our group, infusion of sodium sulfide attenuated kidney injury and 
reduced the inflammatory response after aortic occlusion, although blood sulfide levels were 
hardly affected(34). Thus, measured free bloodsulfide levels do not need to correlate with 
biological effects, either, as H2S-mediated effects might be due to intracellular H2S, which is 
not detected by blood measurements.As the present study is the first to evaluate the effects of 
GYY4137 in swine, we cannot be certain whether the effects were due to intra- or 
extracellular H2S generated from GYY4137, and in our in vivo study it was not possible to 
determine intracellular H2S production. However, given the numerous previously described 
intracellular effects of GYY4137-derived H2S(32) and the rapid rate of exogenous H2S 
removal in blood (e.g. scavenging by hemoglobin etc.) together with the unaffected, 
measured blood sulfide levels, it is most likely, that the observed effects were due to 
intracellular H2S released from GYY4137 rather than extracellular H2S. 
Limitations 
As GYY4137 is a slow-releasing H2S donor, that releases H2S via hydrolysis, we cannot 
exclude the possibility, that the experimental results are influenced by either the mother 
substance itself or the residual molecule after H2S liberation (“decomposed” GYY4137)(35). 
However, as a similar metabolic shift towards preferential carbohydrate utilization has been 
reported with inhaled H2S in mice(6), the present results are most likely attributable to the 
released H2S. Furthermore, “decomposed” GYY4137 did not exert similar cellular effects in 
vitro and in vivo compared to the original compound (15, 35), suggesting that the present 
results are due to GYY4137-derived H2S. However, as discussed above, the dosage of 
GYY4137 might have limited the findings with respect to previously described anti-
inflammatory or organ-protective properties and future studies in large animals should take 
higher dosing into account. Moreover, the metabolic properties with regard to glucose 
oxidation already slightly (but non-significantly) differed between the GYY4137 and the 
control group at the 12 hour time point before the application of GYY4137. Because of the 
small number of animals, we cannot fully exclude the possibility, that the effects reported for 
GYY4137 at 24 hours were due to uneven group distribution. Future studies need to validate 
the reported effects of GYY4137 in larger cohorts.  
Another potential limitation represents the pre-existing cardiovascular comorbidity of the 
FBM swine. As previously reported effects of GYY4137 were evaluated in vitro and in 
Copyright © 2017 by the Shock Society. Unauthorized reproduction of this article is prohibited.
healthy in vivo models, the pre-existing hypercholesterolemia and CAD in our model might 
have influenced the effects of GYY4137 compared to healthy pigs. 
 
Conclusion 
To the best of our knowledge, this is the first study to evaluate effects of the slow-releasing 
H2S donor GYY4137 in large animals. During resuscitated septic shock in swine with pre-
existing atherosclerosis-induced CAD, GYY4137 shifted metabolism to preferential 
carbohydrate utilization under controlled normothermia and reduced arterial pH. Previously 
reported anti-inflammatory and organ-protective properties of GYY4137 in rodents could not 
be demonstrated most likely due to different timing and dosing of GYY4137. Increased 
troponin levels might be due to reduced local availability of NOand deserve further 
investigation.  
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Figure legends 
Figure 1: Glucose metabolism analyzed by combined gas chromatography and mass 
spectrometry (GC/MS). Boxplots display median, quartiles and range. GYY4137 was 
administered 12 and 18 hours after induction of fecal peritonitis, i.e., after the 12 hour time 
point. vehicle: n=8; GYY4137 n=8; n=7 for endogenous glucose production. * p<0.05 
compared to vehicle. 
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Figure 2: Quantitative analysis of western blots and electrophoretic mobility shift assay 
(EMSA) for Nf-κB of heart specimens collected at the end of the experiment. 
For comparison between individual gels, the intensity of each band was related to that of the 
mean of two native animals, which had not undergone surgical instrumentation and faecal 
peritonitis. The mean value of the individual gels for each animal was used for quantitative 
analysis, and data are reported as fold increase over the mean of the two native animals. 
Boxplots display median, quartiles and range. vehicle: n=8 animals; GYY4137 n=7.eNOS: 
endothelial isoform of the nitric oxide synthase; iNOS: inducible isoforms of the nitric oxide 
synthase; HO-1: heme oxygenase-1; Bcl-xL: B-cell lymphoma-extra large; IκBα: inhibitor of 
nuclear factor kappa B; NF-κB: nuclear transcription factor kappa B. 
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Supplemental Figure 1: Original western blots and electrophoretic mobility shift 
assays(EMSA) for Nf-κB of kidney (A) and heart (B) specimens collected at the end of 
the experiments.  
For subsequent comparison between individual gels, the intensity of each band was related to 
that of the mean of two native animals, which had not undergone surgical instrumentation 
and fecal peritonitis. Actin and vinculin served as loading controls. Bcl-xL: B-cell 
lymphoma-extra large; HO-1: heme oxygenase-1; IκBα: inhibitor of nuclear factor kappa B; 
iNOS: inducible isoforms of the nitric oxide synthase; NF-κB: nuclear transcription factor 
kappa B; eNOS: endothelial isoform of the nitric oxide synthase. 
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Table 2: Free sulfide blood concentrations measured with combined gas 
chromatography/mass spectrometry.   
 Before peritonitis 
12 hours 
peritonitis 
24 hours 
peritonitis 
Repeated measures 
two-way ANOVA 
p value for 
treatment 
p value 
for time 
Sulfide 
concentration 
[µmol*L-1] 
Vehicle 
GYY4137 
1.4 
(1.2;1.7) 
1.2 
(1.1;1.5) 
1.8 (1.1;2.3) 
1.2 (0.9;2.0) 
2.4 (1.2;2.8) 
1.5 (1.2;2.3) 0.717 0.083 
All data are expressed as median (25; 75 percentile). GYY4137 was administered 12 and 18 hours 
after induction of fecal peritonitis, i.e., after the 12 hour time point. Control: n=8, GYY4137 n=8 
animals. 
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